Indications / Non-small cell lung cancer · Breast cancer · Pancreatic cancer · Colorectal cancer · Acute myeloid leukemia · Chronic myeloid leukemia · Multiple myeloma · Glioblastoma · Glioma · Neuroblastoma · Medulloblastoma · Diffuse midline glioma (DIPG) · Ependymoma · Atypical teratoid rhabdoid tumour (AT/RT) · Childhood acute lymphoblastic leukemia · Ewing sarcoma · Osteosarcoma · Rhabdomyosarcoma
Medulloblastoma
WNT, SHH, Group 3 and Group 4 disease, and relapse after craniospinal radiotherapy.
Live from ClinicalTrials.gov and PubMed, fetched 2026-11-11 15:18 UTC. Every row links to its source record.
Registry changes (new trials, status, phase, endpoint and readout-date changes, results) come from the OncoSignal store, last verified against ClinicalTrials.gov 2026-11-11 08:26 UTC.
Phase advances
0
since 2026-07-14
New Ph2+ trials
0
Results posted
0
Readouts due
1
primary completion reached
Trial papers
0
PubMed, last 60 days
- Readout dueReadout due: NCT04049669 reached primary completion
Theodore S. Johnson. Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
A phase advance is an asset's first trial at a higher phase than any earlier trial of the same asset in this indication. Readout due means the registry's primary completion date has passed; it is not a disclosure.